Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine

Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology 2003-01, Vol.65 (3), p.198-203
Hauptverfasser: BERARDI, R, PORFIRI, E, CELLERINO, R, SCARTOZZI, M, LIPPE, P, SILVA, R. R, NACCIARRITI, D, MENICHETTI, E. T, TUMMARELLO, D, CARLE, F, PIGA, A
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Medical sciences
Pneumology
Tumors of the respiratory system and mediastinum
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 203
container_issue 3
container_start_page 198
container_title Oncology
container_volume 65
creator BERARDI, R
PORFIRI, E
CELLERINO, R
SCARTOZZI, M
LIPPE, P
SILVA, R. R
NACCIARRITI, D
MENICHETTI, E. T
TUMMARELLO, D
CARLE, F
PIGA, A
description
doi_str_mv 10.1159/000074471
format Article
fullrecord <record><control><sourceid>proquest_pasca</sourceid><recordid>TN_cdi_proquest_journals_220842087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>669590261</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-30f6bbde745b6fe381a385b322a152a84accf0531b9ff18c488552c5396b592b3</originalsourceid><addsrcrecordid>eNotj01PwzAMQCMEEmNw4B9ESBwL-WxTbtO0waRJcIBz5aTp1pFlXZMy7d-TabNk--DnZxmhR0peKJXlK0lRCFHQKzSigvGMMM6u0YgQTjImqLhFdyFsTpQU-QjtZ662vTviL4it9THgQxvXGOo_8MbW2O98FrbgHDY2FTf4FTanUf-GJ7hbQ7B4scAhDvXxvHqw9jf5TBs6l5weg6_xym5NG0G33t6jmwZcsA-XPkY_89n39CNbfr4vppNl1jFKYsZJk2td20JInTeWKwpcSc0ZAyoZKAHGNERyqsumocoIpaRkRvIy17Jkmo_R09nb9bv9YEOsNruh9-lkxRhRImWRoOcLBMGAa_r0Whuqrm-30B8rKjlTinL-D-7FZ1s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220842087</pqid></control><display><type>article</type><title>Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine</title><source>Karger Journals</source><creator>BERARDI, R ; PORFIRI, E ; CELLERINO, R ; SCARTOZZI, M ; LIPPE, P ; SILVA, R. R ; NACCIARRITI, D ; MENICHETTI, E. T ; TUMMARELLO, D ; CARLE, F ; PIGA, A</creator><creatorcontrib>BERARDI, R ; PORFIRI, E ; CELLERINO, R ; SCARTOZZI, M ; LIPPE, P ; SILVA, R. R ; NACCIARRITI, D ; MENICHETTI, E. T ; TUMMARELLO, D ; CARLE, F ; PIGA, A</creatorcontrib><description><![CDATA[<Objectives:< The incidence of non-small cell lung cancer (NSCLC) is increasing among the elderly. We studied the toxicity and efficacy of a weekly schedule of gemcitabine and cisplatin in elderly patients with advanced NSCLC. <Methods:< Patients aged 70 years or above with advanced NSCLC were treated in a phase II prospective trial with gemcitabine 1,000 mg/m<2< and cisplatin 35 mg/m<2< on days 1, 8 and 15 every 28 days. <Results:< Forty-eight patients with a median age of 74 years (range 70-78) participated in the study. We observed 14 cases with partial response, 14 with stable disease and 16 with progressive disease, whilst 4 patients were not evaluable. By intention-to-treat analysis, partial response rate was 31.8% whilst progressive disease was 33.3%. Median survival was 9 months; 1-year survival probability was 34.4% and median time to progression was 4 months. Grade III-IV leukopenia was observed in 5/48 patients (10.4%), 20/48 patients (41.7%) had grade III-IV thrombocytopenia and 7/48 patients (14.6%) had grade III-IV anemia. One patient experienced grade III emesis and 2 patients had grade III-IV fatigue. <Conclusions:< At this dose and schedule the combination of gemcitabine and cisplatin appears to be an active and well-tolerated regimen for elderly patients with advanced NSCLC. Copyright © 2003 S. Karger AG, Basel]]></description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000074471</identifier><language>eng</language><publisher>Basel: Karger</publisher><subject>Biological and medical sciences ; Medical sciences ; Pneumology ; Tumors of the respiratory system and mediastinum</subject><ispartof>Oncology, 2003-01, Vol.65 (3), p.198-203</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright (c) 2003 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15328813$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>BERARDI, R</creatorcontrib><creatorcontrib>PORFIRI, E</creatorcontrib><creatorcontrib>CELLERINO, R</creatorcontrib><creatorcontrib>SCARTOZZI, M</creatorcontrib><creatorcontrib>LIPPE, P</creatorcontrib><creatorcontrib>SILVA, R. R</creatorcontrib><creatorcontrib>NACCIARRITI, D</creatorcontrib><creatorcontrib>MENICHETTI, E. T</creatorcontrib><creatorcontrib>TUMMARELLO, D</creatorcontrib><creatorcontrib>CARLE, F</creatorcontrib><creatorcontrib>PIGA, A</creatorcontrib><title>Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine</title><title>Oncology</title><description><![CDATA[<Objectives:< The incidence of non-small cell lung cancer (NSCLC) is increasing among the elderly. We studied the toxicity and efficacy of a weekly schedule of gemcitabine and cisplatin in elderly patients with advanced NSCLC. <Methods:< Patients aged 70 years or above with advanced NSCLC were treated in a phase II prospective trial with gemcitabine 1,000 mg/m<2< and cisplatin 35 mg/m<2< on days 1, 8 and 15 every 28 days. <Results:< Forty-eight patients with a median age of 74 years (range 70-78) participated in the study. We observed 14 cases with partial response, 14 with stable disease and 16 with progressive disease, whilst 4 patients were not evaluable. By intention-to-treat analysis, partial response rate was 31.8% whilst progressive disease was 33.3%. Median survival was 9 months; 1-year survival probability was 34.4% and median time to progression was 4 months. Grade III-IV leukopenia was observed in 5/48 patients (10.4%), 20/48 patients (41.7%) had grade III-IV thrombocytopenia and 7/48 patients (14.6%) had grade III-IV anemia. One patient experienced grade III emesis and 2 patients had grade III-IV fatigue. <Conclusions:< At this dose and schedule the combination of gemcitabine and cisplatin appears to be an active and well-tolerated regimen for elderly patients with advanced NSCLC. Copyright © 2003 S. Karger AG, Basel]]></description><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Pneumology</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNotj01PwzAMQCMEEmNw4B9ESBwL-WxTbtO0waRJcIBz5aTp1pFlXZMy7d-TabNk--DnZxmhR0peKJXlK0lRCFHQKzSigvGMMM6u0YgQTjImqLhFdyFsTpQU-QjtZ662vTviL4it9THgQxvXGOo_8MbW2O98FrbgHDY2FTf4FTanUf-GJ7hbQ7B4scAhDvXxvHqw9jf5TBs6l5weg6_xym5NG0G33t6jmwZcsA-XPkY_89n39CNbfr4vppNl1jFKYsZJk2td20JInTeWKwpcSc0ZAyoZKAHGNERyqsumocoIpaRkRvIy17Jkmo_R09nb9bv9YEOsNruh9-lkxRhRImWRoOcLBMGAa_r0Whuqrm-30B8rKjlTinL-D-7FZ1s</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>BERARDI, R</creator><creator>PORFIRI, E</creator><creator>CELLERINO, R</creator><creator>SCARTOZZI, M</creator><creator>LIPPE, P</creator><creator>SILVA, R. R</creator><creator>NACCIARRITI, D</creator><creator>MENICHETTI, E. T</creator><creator>TUMMARELLO, D</creator><creator>CARLE, F</creator><creator>PIGA, A</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope></search><sort><creationdate>20030101</creationdate><title>Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine</title><author>BERARDI, R ; PORFIRI, E ; CELLERINO, R ; SCARTOZZI, M ; LIPPE, P ; SILVA, R. R ; NACCIARRITI, D ; MENICHETTI, E. T ; TUMMARELLO, D ; CARLE, F ; PIGA, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-30f6bbde745b6fe381a385b322a152a84accf0531b9ff18c488552c5396b592b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Pneumology</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BERARDI, R</creatorcontrib><creatorcontrib>PORFIRI, E</creatorcontrib><creatorcontrib>CELLERINO, R</creatorcontrib><creatorcontrib>SCARTOZZI, M</creatorcontrib><creatorcontrib>LIPPE, P</creatorcontrib><creatorcontrib>SILVA, R. R</creatorcontrib><creatorcontrib>NACCIARRITI, D</creatorcontrib><creatorcontrib>MENICHETTI, E. T</creatorcontrib><creatorcontrib>TUMMARELLO, D</creatorcontrib><creatorcontrib>CARLE, F</creatorcontrib><creatorcontrib>PIGA, A</creatorcontrib><collection>Pascal-Francis</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BERARDI, R</au><au>PORFIRI, E</au><au>CELLERINO, R</au><au>SCARTOZZI, M</au><au>LIPPE, P</au><au>SILVA, R. R</au><au>NACCIARRITI, D</au><au>MENICHETTI, E. T</au><au>TUMMARELLO, D</au><au>CARLE, F</au><au>PIGA, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine</atitle><jtitle>Oncology</jtitle><date>2003-01-01</date><risdate>2003</risdate><volume>65</volume><issue>3</issue><spage>198</spage><epage>203</epage><pages>198-203</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract><![CDATA[<Objectives:< The incidence of non-small cell lung cancer (NSCLC) is increasing among the elderly. We studied the toxicity and efficacy of a weekly schedule of gemcitabine and cisplatin in elderly patients with advanced NSCLC. <Methods:< Patients aged 70 years or above with advanced NSCLC were treated in a phase II prospective trial with gemcitabine 1,000 mg/m<2< and cisplatin 35 mg/m<2< on days 1, 8 and 15 every 28 days. <Results:< Forty-eight patients with a median age of 74 years (range 70-78) participated in the study. We observed 14 cases with partial response, 14 with stable disease and 16 with progressive disease, whilst 4 patients were not evaluable. By intention-to-treat analysis, partial response rate was 31.8% whilst progressive disease was 33.3%. Median survival was 9 months; 1-year survival probability was 34.4% and median time to progression was 4 months. Grade III-IV leukopenia was observed in 5/48 patients (10.4%), 20/48 patients (41.7%) had grade III-IV thrombocytopenia and 7/48 patients (14.6%) had grade III-IV anemia. One patient experienced grade III emesis and 2 patients had grade III-IV fatigue. <Conclusions:< At this dose and schedule the combination of gemcitabine and cisplatin appears to be an active and well-tolerated regimen for elderly patients with advanced NSCLC. Copyright © 2003 S. Karger AG, Basel]]></abstract><cop>Basel</cop><pub>Karger</pub><doi>10.1159/000074471</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0030-2414
ispartof Oncology, 2003-01, Vol.65 (3), p.198-203
issn 0030-2414
1423-0232
language eng
recordid cdi_proquest_journals_220842087
source Karger Journals
subjects Biological and medical sciences
Medical sciences
Pneumology
Tumors of the respiratory system and mediastinum
title Elderly Patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A04%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elderly%20Patients%20with%20advanced%20non-small%20cell%20lung%20cancer:%20A%20phase%20II%20study%20with%20weekly%20cisplatin%20and%20gemcitabine&rft.jtitle=Oncology&rft.au=BERARDI,%20R&rft.date=2003-01-01&rft.volume=65&rft.issue=3&rft.spage=198&rft.epage=203&rft.pages=198-203&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000074471&rft_dat=%3Cproquest_pasca%3E669590261%3C/proquest_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220842087&rft_id=info:pmid/&rfr_iscdi=true